Loading...
•
Dec 31, 2022
Health Catalyst Q4 2022 Earnings Report
Achieved strong performance, exceeding revenue and Adjusted EBITDA guidance for Q4 2022.
Key Takeaways
Health Catalyst reported strong Q4 2022 results, exceeding revenue and Adjusted EBITDA guidance. The company also announced the appointment of Matthew Kolb to its Board of Directors and a deepened investment from Carle Health.
Achieved strong performance across the business in Q4 2022, exceeding the mid-point of quarterly guidance for both revenue and Adjusted EBITDA.
Adjusted EBITDA outperformed the mid-point of the original full year guidance provided entering 2022.
Matthew Kolb, Executive Vice President and Chief Operating Officer of Carle Health, will be joining the Health Catalyst Board of Directors, effective July 1, 2023.
Carle Health has made the decision to deepen its long-term investment in Health Catalyst with a meaningful purchase on the open market of Health Catalyst’s common stock.
Health Catalyst
Health Catalyst
Forward Guidance
For the first quarter of 2023, Health Catalyst expects total revenue between $70.3 million and $72.3 million, and Adjusted EBITDA between $1.0 million and $2.5 million. For the full year of 2023, the company expects total revenue between $290 million and $295 million, and Adjusted EBITDA between $9.0 million and $11.0 million.
Positive Outlook
- Total revenue between $70.3 million and $72.3 million for Q1 2023
- Adjusted EBITDA between $1.0 million and $2.5 million for Q1 2023
- Total revenue between $290 million and $295 million for the full year 2023
- Adjusted EBITDA between $9.0 million and $11.0 million for the full year 2023